Press Releases

Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™  (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults Ocugen has North American commercialization rights for COVAXIN™ MALVERN, Pa., June 21, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc.

MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen , Inc . (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among the

Issuance of U.S. Patent No. 11,351,225 Further Enhances Ocugen’s Gene Therapy Intellectual Property Portfolio MALVERN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene

MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen , Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that Michael Shine, Ocugen’s Senior Vice President, Commercial, will present

NeoCart ® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines MALVERN, Pa., May 24, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and

MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will

Dosing to Resume Immediately MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that the U.S.

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after DSMB review Ocugen’s exclusive territory for COVAXIN™ (BBV152) marketing expanded to include

MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced that it will host a conference call to provide a business update and discuss its

MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company’s research into the development of a modifier